Heribert Hanscheid
Overview
Explore the profile of Heribert Hanscheid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campenni A, Avram A, Verburg F, Iakovou I, Hanscheid H, de Keizer B, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jul;
50(11):3324-3348.
PMID: 37395802
This document provides the new EANM guideline on radioiodine therapy of benign thyroid disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners in the selection of patients ...
2.
Hartlapp I, Hartrampf P, Serfling S, Wild V, Weich A, Rasche L, et al.
J Nucl Med
. 2023 Jun;
64(9):1424-1430.
PMID: 37348915
Desmoplastic small round cell tumor (DSRCT) is a rare, radiosensitive, yet difficult-to-treat sarcoma subtype affecting predominantly male adolescents. Extensive intraperitoneal seeding is common and requires multimodal management. With no standard...
3.
Werner R, Sayehli C, Hanscheid H, Higuchi T, Serfling S, Fassnacht M, et al.
Eur J Nucl Med Mol Imaging
. 2022 Dec;
50(6):1833-1834.
PMID: 36522435
No abstract available.
4.
Hanscheid H, Lassmann M, Verburg F
Z Med Phys
. 2022 Nov;
33(1):82-90.
PMID: 36376202
In radionuclide therapy, activity kinetics in tissues determine the absorbed doses administered and thus efficacy and side effects of treatment. The objective of this work was to derive expressions for...
5.
Buck A, Grigoleit G, Kraus S, Schirbel A, Heinsch M, Dreher N, et al.
J Nucl Med
. 2022 Jun;
64(1):34-39.
PMID: 35738903
C-X-C motif chemokine receptor 4 (CXCR4)-targeted radioligand therapy (RLT) has already been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell lymphoma. We present a series...
6.
Buck A, Serfling S, Lindner T, Hanscheid H, Schirbel A, Hahner S, et al.
Eur J Nucl Med Mol Imaging
. 2022 Jun;
49(12):4133-4144.
PMID: 35674738
A growing body of literature reports on the upregulation of C-X-C motif chemokine receptor 4 (CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for molecular...
7.
Hahner S, Hartrampf P, Mihatsch P, Nauerz M, Heinze B, Hanscheid H, et al.
J Clin Endocrinol Metab
. 2021 Dec;
107(4):e1348-e1355.
PMID: 34904171
Context: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options. Theranostic approaches with adrenal specific radiotracers hold promise for improved diagnostics and treatment. Objective: Here, we report...
8.
Reiners C, Hanscheid H, Schneider R
J Radiol Prot
. 2021 Sep;
41(4).
PMID: 34547726
Without any doubt, high dose radiation exposure can induce hypothyroidism. However, there are open questions related to the mechanisms of its induction, corresponding dose thresholds and possible countermeasures. Therefore, this...
9.
Hanscheid H, Schirbel A, Hartrampf P, Kraus S, Werner R, Einsele H, et al.
J Nucl Med
. 2021 Aug;
63(5):754-760.
PMID: 34413147
The chemokine receptor 4 (CXCR4), which is overexpressed in many solid and hematologic malignancies, can be targeted for radiopeptide therapy via the antagonist pentixather. The biokinetics and dosimetry of Lu-pentixather...
10.
Kertels O, Breun M, Hanscheid H, Kircher M, Hartrampf P, Schirbel A, et al.
Clin Nucl Med
. 2021 Apr;
46(6):e312-e316.
PMID: 33826573
Purpose: Neurofibromatosis type 2 (NF2) is a genetic disorder that is associated with multiple tumors of the nervous system, and approximately one half of patients present with meningiomas. For patients...